Termination of Early Pregnancy in Scarred Uterus With Lletrozole and Misoprostol Compared to Misoprostol Alone
1 other identifier
observational
1
1 country
2
Brief Summary
Termination of early pregnancy in scarred uterus with letrozole and misoprostol compared to Misoprostol alone
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started Oct 2021
Shorter than P25 for all trials
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
September 23, 2021
CompletedStudy Start
First participant enrolled
October 1, 2021
CompletedFirst Posted
Study publicly available on registry
October 5, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 1, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
August 1, 2022
CompletedOctober 5, 2021
September 1, 2021
6 months
September 23, 2021
September 23, 2021
Conditions
Outcome Measures
Primary Outcomes (1)
Complete abortion of early pregnancy with letrozole then misoprostol
Letrozole increase cervical ripening
6 months
Study Arms (2)
Missed abortion received letrozole then misoprostol
Missed abortion received misoprostol alone
Interventions
Missed abortion received letrozole then misoprostol
Eligibility Criteria
Termination of early pregnancy in scarred uterus with letrozole and misoprostol compared to Misoprostol alone
You may qualify if:
- Minimum age of 18 years for mother.
- Non-viable fetus (missed abortion or blighted ovum) in the 1st trimester of pregnancy evidenced by criteria for diagnosis by TVS .
- Previous C.S or Myomectomy (1 or more )
- lack of any maternal diseases such as: heart disease, asthma, history of thromboembolism, cancer, renal failure, and liver diseases.
You may not qualify if:
- \* Medical problem in patient
- Emergency conditions which need intervention .
- History of allergy to misoprostol or letrozole drugs.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (2)
Ahmed Elsayed Aref
Sohag, Egypt
Ahmed Elsayed Aref
Sohag, Egypt
MeSH Terms
Interventions
Intervention Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- Ahmed Elsayed Aref
Study Record Dates
First Submitted
September 23, 2021
First Posted
October 5, 2021
Study Start
October 1, 2021
Primary Completion
April 1, 2022
Study Completion
August 1, 2022
Last Updated
October 5, 2021
Record last verified: 2021-09